<DOC>
	<DOC>NCT00433017</DOC>
	<brief_summary>This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration</brief_summary>
	<brief_title>Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects of either gender age 50 years or older Subfoveal choriodal neovascularization (CNV) due to agerelated macular degeneration (AMD) Choriodal neovascularization due to causes other than AMD Prior treatment for neovascular AMD in the study eye Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>